Animal cell-based expression platforms enable the production of complex biomolecules
such as recombinant proteins and viral vectors. Although most biotherapeutics are produced …

Infectious diseases, along with cancers, are among the main causes of death among
humans worldwide. The production of therapeutic proteins for treating diseases at large …

The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing
steadily, which is attracting global attention for the development of new recombinant protein …

Recombinant proteins used in biomedical research, diagnostics and different therapies are
mostly produced in Chinese hamster ovary cells in the pharmaceutical industry. These …

The manufacturing of recombinant protein is traditionally undertaken in mammalian cell
culture. Today, speed, cost and safety are the primary considerations for process …

Highlights•Mathematical models as tools to establish quantitative links between bioprocess
CPPs and KPIs.•Review of the advantages and limitations of mechanistic and statistical …

Nearly 80% of the approved human therapeutic antibodies are produced by Chinese
Hamster Ovary (CHO) cells. To achieve better cell growth and high-yield recombinant …

As the sole target of broadly neutralizing antibodies (bnAbs) to HIV, the envelope
glycoprotein (Env) trimer is the focus of vaccination strategies designed to elicit protective …

Highlights•The CHO genome suffers from chromosomal rearrangements and other stability-
related issues.•The CHO cell instability phenotype is characterized by titer instability and …

Advances in nuclease-based gene-editing technologies have enabled precise, stable, and
systematic genetic engineering of glycosylation capacities in mammalian cells, opening up a …